ABSTRACT Nearly 40% of children with Anaplastic Large cell lymphomas will relapse after a first-line strategy with short-pulse chemotherapy and reach a second remission in 30% to 60% with second line therapies including maintenance treatment with vinblastine or allogeneic hematopoietic stem-cell transplantation.The authors report a heavily pretreated case in second relapse who was maintained in third remission for 8 years with monthly vinblastine. He relapsed 16 weeks after discontinuation.This case demonstrates that monthly treatment with vinblastine may be sufficient to maintain a minimal disease. Oral compounds are now available and should be discussed in such situations.
Cite this paper
R. Mlis, M. Schell, P. Bérard, N. Bleyzac and D. Frappaz, "Long Lasting Efficiency of Monthly Vinblastine in a Case of Relapsed Anaplastic Large Cell Lymphoma," Open Journal of Blood Diseases, Vol. 3 No. 2, 2013, pp. 63-64. doi: 10.4236/ojbd.2013.32013.
 L. Brugieres, P. Quartier, M. C. Le Deley, H. Pacquement, Y. Perel, C. Bergeron, et al., “Relapses of Childhood Anaplastic Large-Cell Lymphoma: Treatment Results in a Series of 41 Children—A Report from the French Society of Pediatric Oncology,” Annals of Oncology, Vol. 11, No. 1, 2000, pp. 53-58. doi:10.1023/A:1008352726155
 M. A. Jordan, D. Thrower and L. Wilson, “Effects of Vinblastine, Podophyllotoxin and Nocodazole on Mitotic Spindles. Implications for the Role of Microtubule Dynamics in Mitosis,” Journal of Cell Science, Vol. 102, 1992, pp. 401-416.
 R. J. Owellen, C. A. Hartke and F. O. Hains, “Pharmacokinetics and Metabolism of Vinblastine in Humans,” Cancer Research, Vol. 37, No. 8, 1977, pp. 2597-2602.
 E. Bouffet, R. Jakacki, S. Goldman, D. Hargrave, C. Hawkins, M. Shroff, et al., “Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma,” Journal of Clinical Oncology, Vol. 30, No. 12, 2012, pp. 1358-1363.